Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2009
Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
2010
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
2010
The treatment of early breast cancer in women over the age of 70
2011
Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
2010
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
2012
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
1999 Standout
Role of Transforming Growth Factor β in Human Disease
2000 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting
2000
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Clinical applications of quinone-containing alkylating agents
2000
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2005
Antitumour actions of interferons: implications for cancer therapy
2016
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta
1995
Significance, detection and markers of disseminated breast cancer cells
2006
Lung cancer: current therapies and new targeted treatments
2016 Standout
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
2006
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer
2010
Chronic Health Conditions in Adult Survivors of Childhood Cancer
2006 Standout
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
2012
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression
2001 StandoutNobel
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
2014
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
1998 Standout
Bladder cancer
2016 Standout
On the Dependency of Cellular Protein Levels on mRNA Abundance
2016 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
2012
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Mass spectrometric protein maps for biomarker discovery and clinical research
2013
Exosomes in tumor microenvironment influence cancer progression and metastasis
2013
Chemotherapy for Malignant Pleural Mesothelioma
2003
Fertility Preservation Methods in Breast Cancer
2012
Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
1996
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
2013
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer
2003
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis
2012
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids
1995 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women
1991
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
Advances in Malignant Mesothelioma
2005 Standout
Late effects of childhood cancer therapy
2002
Molecular biology and targeted therapies for urothelial carcinoma
2015
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Fluorine in medicinal chemistry
2007 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Chemotherapy for advanced non-small cell lung cancer in the elderly population
2015
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
2009
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Chemotherapy of advanced non-small cell lung cancer
1999
Time to Begin Adjuvant Chemotherapy and Survival in Breast Cancer Patients: A Retrospective Observational Study Using Latent Class Analysis
2013
Breast Cancer Treatment
2019 Standout
Lipoplatin Formulation Review Article
2011
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
2000
The expanding utility of continuous flow hydrogenation
2015
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
2014 Standout
Tamoxifen for early breast cancer: an overview of the randomised trials
1998 Standout
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
1991
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium
2006
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
2012
Works of P. Pronzato being referenced
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses
2013
HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
2007
A Dose Finding Study of Carboplatin and Gemcitabine in Advanced Non-Small Cell Lung Cancer
2002
New Understanding of the Role of Anthracyclines in Early-Stage Breast Cancer: Patient Selection Considerations
2008
A Randomized Trial on Tamoxifen Continuation during Second‐Line Hormone Therapy in Breast Cancer
1993
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial
2011
Second Line Chemotherapy with Ifosfamide as Outpatient Treatment for Advanced Bladder Cancer
1997
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
1996
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
2005
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO)
1996
Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer
2011
Cisplatin and recombinant alpha interferon in advanced breast cancer
1990
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity
2009
Tamoxifen and interferon-beta for the treatment of metastatic breast cancer
1996
Lymphoblastoid Interferon in Advanced Breast Cancer: a Phase II study
1993
Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
1988
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study
2002
Tamoxifen and Alpha Interferon in Advanced Breast Cancer
1991
Impact of Administration-Related Factors on Outcome of Adjuvant Chemotherapy for Primary Breast Cancer
1989
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
2013
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma
1997
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group
2007
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
2009
Granisetron-dexamethasone combination for multiple day cisplatin.
1996
Docetaxel (D) versus docetaxel/gemcitabine (D&G) in the treatment of older patients with advanced non-small cell lung cancer (NSCLC): An Alpe Adria Thoracic Oncology Multidisciplinary Group randomized phase II trial (ATOM 017).
2010
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
2012
Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.
1994
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
1987
Relationship between human mammaglobin mRNA expression in breast cancer tissue and clinico-pathologic features of the tumors.
2006
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
2012
Breast cancer in elderly women: a different reality? Results from the NORA study
2007
Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review
2011
Effect of fulvestrant treatment on serum VEGF levels in hormone-sensitive metastatic breast cancer patients
2009